We then analyzed an in-house gene profiling dataset of seven matched metastatic tumor samples obtained from a cohort of patients before therapy and after the onset of treatment resistance for expression values of PTGS2 and of a number of additional direct or indirect miR-146a targets. This evidence concerns the gene PTGS2 and metastatic neoplasm.